All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Mikrobiomik secures Spain approval for EUTEGRA (MBK-01) gut microbiota therapy targeting Clostridioides difficile infection
Microbiota therapy, infectious disease, fecal microbiota transplant, Clostridioides difficile infection, gut microbiome - Read more

THE GOOD
Business Development & Partnerships

Manus Bio secures $15M US government contract for domestic flu drug component supply
Manufacturing agreement, infectious disease, synthetic biology, domestic supply chain - Read more

IBA, Shreeji sign multi-site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing, €5-7M ($5.88 - 8.24M)
Manufacturing agreement, diagnostics, radiopharmaceuticals, milestone payments - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Merck & Co.'s Enflonsia (clesrovimab) shows positive Ph3 results for second-season respiratory syncytial virus prevention
Antibody, infectious disease, monoclonal antibody, RSV, pediatric population, prevention - Read more

ViiV Healthcare's Cabenuva (cabotegravir/rilpivirine) demonstrates superiority over daily antiretroviral therapy in Ph3 human immunodeficiency virus study
Combination therapy, infectious disease, injectable, HIV, cabotegravir, rilpivirine - Read more

Brenus Pharma presents preclinical data for STC-1010 targeting microsatellite stable colorectal cancer at AACR conference
Immunotherapy, cancer, colorectal cancer, MSS tumors, dendritic cell activation, T cell priming - Read more

Takeda's ENTYVIO (vedolizumab) shows positive Ph3 results for pediatric moderate to severe ulcerative colitis
Antibody, autoimmune, monoclonal antibody, ulcerative colitis, integrin inhibitor, pediatric population - Read more

THE GOOD
Earnings & Finances

Insmed CEO defends "audacious" $1B Brinsupri 2026 sales projection after strong Q4 launch performance
Small molecule, respiratory, financial, strategic - Read more

Madrigal Pharmaceuticals reports Rezdiffra sales of $958.4M in 2025, narrowly missing $1B milestone amid Novo competition
Small molecule, metabolic disease, competitive, revenue impact - Read more

THE GOOD
Fundraises

Altesa BioSciences raises $75M Series B, advancing lung drug vapendavir
Small molecule, respiratory disease, antiviral, clinical-stage - Read more

Lario Therapeutics awarded $2.4M grants, advancing calcium channel neurological platform
Neurological, small molecule, calcium channel platform, precision medicine - Read more

Eupraxia Pharmaceuticals raises $55M public offering, advancing EP-104GI gastrointestinal treatments
Clinical-stage, controlled drug delivery, gastrointestinal, platform technology - Read more

Sift Biosciences raises $3.7M Pre-Seed, peptide-based immunotherapy platform for oncology
Peptide-based immunotherapy, oncology, autoimmune, AI-driven, platform technology - Read more

Step Pharma raises €2.5M ($2.9M) grant, targeted cancer therapies for CTPS2 null tumors
Cancer, small molecule, precision oncology, clinical-stage - Read more

Ten63 Therapeutics closes strategic financing, bringing total funding over $45M for AI drug discovery
AI/ML platform, drug discovery, oncology, small molecule, platform technology, undruggable targets - Read more

THE GOOD
Product Launches

Zydus Lifesciences launches India's first indigenous Aflibercept biosimilar ANYRA for retinal diseases
Biosimilar, ophthalmology, strategic, market access - Read more

THE GOOD
Regulatory

FDA announces one pivotal trial will be default standard for drug approvals, ending two-trial requirement
Regulatory, strategic, operational, financial - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Novartis discontinues QEQ278 Ph1 trial in advanced solid tumors after lacking efficacy in 30 patients
Protein therapy, cancer, solid tumors, advanced malignancies - Read more

J&J halts enrollment in Ph2 trial of AC Immune-partnered ACI-35.030 (JNJ-2056) for Alzheimer's disease
Immunotherapy, neurological, anti-tau antibody, Alzheimer's disease, presymptomatic population - Read more

Biogen terminates BIIB091 (BTK inhibitor) Ph2 study for relapsing multiple sclerosis after enrolling 127 patients
Small molecule, neurological, BTK inhibitor, multiple sclerosis, combination therapy - Read more

THE BAD
Regulatory

CDC postpones key vaccine advisory panel meeting amid policy upheaval and leadership changes
mRNA vaccine, infectious disease, regulatory, operational - Read more

FDA issues untitled letter criticizing J&J's Tremfya ad for misleading efficacy claims in ulcerative colitis
Monoclonal antibody, autoimmune, regulatory, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here